Acquisition Has Love Pharma’s Naltrexone on NIH Shortlist to Address Unmet Medical Need—Treatment for Long Covid NEW YORK, NY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Love Pharma Inc. (CSE: LUV) (FSE: G1Q0), an international mental health and sexual wellness company, has been explicit about its plans to develop a...

Love Pharma’s Investment in US Biotech Offers Strategic Industry Advantages and Enhanced Shareholder Value NEW YORK, NY, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Love Pharma Inc. (CSE: LUV) (FSE: G1Q0), an international mental health and sexual wellness company, remains extremely active in shaping itself into...

Love Pharma’s Acquisition Will Offer Exclusive Partnership and License with World Renowned University to Conduct Landmark Psilocybin Study NEW YORK, NY, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) continues to prioritize the necessity for clinical validation as a vital step in bringing its products to...

LOVE Pharma Announces Debut of New Products, BLOOM™ and AURALIEF™ VANCOUVER, BC CANADA, Oct. 27, 2021 (GLOBE NEWSWIRE) -- LOVE Pharma Co. (CSE: LUV) (FSE: G1Q0), the Company is pleased to announce the debut of its first two products, BLOOM™ and AURALIEF™. ...

Love Pharma Makes Public Debut in Emerging Sexual Health, Wellness, and Psychedelics Markets NEW YORK, NY, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Love Pharma Inc. (CSE: LUV), formerly Glenbriar Technologies, Inc., is a new-age pharma/nutraceutical company that specializes in the global sexual...